<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04439708</url>
  </required_header>
  <id_info>
    <org_study_id>C18-08</org_study_id>
    <secondary_id>2018-A02099-46</secondary_id>
    <nct_id>NCT04439708</nct_id>
  </id_info>
  <brief_title>Biomarkers and Choroidal Neovascularization</brief_title>
  <acronym>BioNéoRet</acronym>
  <official_title>Biomarkers Analysis of Mineralocortoid Receptor Activation in the Serum and Ocular Fluid of Patients With Choroidal Neovascularization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to find biomarkers in the blood and aqueous humor of patients with
      type 1 choroidal neovascularization and correlate them with the response to anti-VEGF
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Age-related macular degeneration (AMD) is the most frequent cause of blindness in
      industrialized countries. Multiple molecular pathways have been implicated in the
      pathogenesis of choroidal neovascularization (CNV). Currently, the treatment relies on
      neutralization of VEGF (Vascular Endothelial Growth Factor). However some patients have an
      incomplete response to anti-VEGF treatment. A recent study suggested the implication of the
      mineralocorticoid receptor pathway in the formation of CNV.

      The study (of investigators) aim is to evaluate the concentation of metabolites of MR pathway
      in the blood and aqueous humor of patients with CNV and compared them with patients without
      CNV in order to increase our understanding of CNV pathogenesis and find potential biomarker
      of response to anti-VEGF treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>biomarker analysis in blood and aqueous humor of patients with neovascularization and controls</measure>
    <time_frame>24 months</time_frame>
    <description>Biomarker concentrations (pg/ml) will be evaluated with ELISA (Enzyme Linked ImmunoSorbent Assay).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>biomarker analysis in blood and aqueous humor of patients with neovascularization and controls</measure>
    <time_frame>24 months</time_frame>
    <description>Biomarker concentrations (pg/ml) will be evaluated with Mulitplex Biorad.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>biomarkers and treatment response</measure>
    <time_frame>24 months</time_frame>
    <description>Correlation between biomarker level and the response to anti-VEGF treatment</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Choroidal Neovascularization</condition>
  <condition>Mineralocorticoid Excess</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Patients with choroidal neovascularization in the context of age-related macular degeneration or central serous chorioretinopathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Control group : patients without choroidal neovascularization</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood and aqueous humor biomarker of treatment response</intervention_name>
    <description>Blood analyses and aqueous humor analysis</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood and aqueous humor samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Group 1 : patients with type 1 choroidal neovascularization Group 2: patients without
        choroidal neovascularization before ocular surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients of group 1:

          -  Patients with type 1 choroidal neovascularization in a context of central serous
             chorioretinoathy or age related macular degeneration

          -  Patients without intravitreal injection or last intravitreal injection &gt; 3 months

          -  Informed signed consent

        Patients of group 2:

          -  Patients without choroidal neovascularization

          -  Patients with intraocular surgery (cataract or vitrectomy surgery)

          -  Signed consent

        Exclusion Criteria:

          -  Myocardial infarction &lt; 12 months

          -  Chronic renal failure

          -  Inflammatory disease

          -  Infectious disease :HIV, viral hepatitis, tuberculosis

          -  Type 1 or 2 Diabetes

          -  Patients treated by mineralocorticoid antagonist treatment.

          -  Type 2 or 3 choroidal neovascularization

          -  Pregnant woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Francine Behar-Cohen, Dr</last_name>
    <phone>01 44 27 81 64</phone>
    <email>francine.cohen@aphp.fr</email>
  </overall_contact>
  <reference>
    <citation>Suzuki M, Nagai N, Izumi-Nagai K, Shinoda H, Koto T, Uchida A, Mochimaru H, Yuki K, Sasaki M, Tsubota K, Ozawa Y. Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration. Br J Ophthalmol. 2014 Sep;98(9):1186-91. doi: 10.1136/bjophthalmol-2013-304670. Epub 2014 Apr 7.</citation>
    <PMID>24711658</PMID>
  </reference>
  <reference>
    <citation>Kersten E, Paun CC, Schellevis RL, Hoyng CB, Delcourt C, Lengyel I, Peto T, Ueffing M, Klaver CCW, Dammeier S, den Hollander AI, de Jong EK. Systemic and ocular fluid compounds as potential biomarkers in age-related macular degeneration. Surv Ophthalmol. 2018 Jan - Feb;63(1):9-39. doi: 10.1016/j.survophthal.2017.05.003. Epub 2017 May 15. Review.</citation>
    <PMID>28522341</PMID>
  </reference>
  <reference>
    <citation>Rezar-Dreindl S, Sacu S, Eibenberger K, Pollreisz A, Bühl W, Georgopoulos M, Krall C, Weigert G, Schmidt-Erfurth U. The Intraocular Cytokine Profile and Therapeutic Response in Persistent Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2016 Aug 1;57(10):4144-50. doi: 10.1167/iovs.16-19772.</citation>
    <PMID>27537264</PMID>
  </reference>
  <reference>
    <citation>Zhao M, Mantel I, Gelize E, Li X, Xie X, Arboleda A, Seminel M, Levy-Boukris R, Dernigoghossian M, Prunotto A, Andrieu-Soler C, Rivolta C, Canonica J, Naud MC, Lechner S, Farman N, Bravo-Osuna I, Herrero-Vanrell R, Jaisser F, Behar-Cohen F. Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration. Nat Commun. 2019 Jan 21;10(1):369. doi: 10.1038/s41467-018-08125-6.</citation>
    <PMID>30664640</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>June 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2020</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>central serous chorioretinopathy</keyword>
  <keyword>age related macular degeneration</keyword>
  <keyword>biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Hyperaldosteronism</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

